Menomonie, Wis. (PRWEB) July 09, 2014
Dr. Srivastava was most recently Senior Research Scientist of the Anticonvulsant Drug Development Program at the University of Utah where he developed a novel animal model of pharmaco-resistant epilepsy to screen the potential antiepileptic drugs. Dr. Srivastava is one of the pioneer researchers on the role of antioxidants resveratrol and melatonin in epilepsy. He has 20 years of experience in drug development and nutraceutical research.
Raj Lall, President and CEO of Vets Plus, Inc. said he is excited about the formulation and product development experience Dr. Srivastava brings to the position. “Dr. Srivastava has a veterinary and pharmacology background and experience in clinical trials. He is an innovative thinker who will be a great addition to our research team.”
Dr. Srivastava was recently invited to deliver a presentation on the benefits of nutraceuticals for cognitive health in aging pets at the National Animal Supplement Council (NASC) Annual Conference. At Vets Plus, he will focus on pre-clinical and clinical efficacy and safety studies of products for companion animals. He will be involved with product formulation and development, as well as literature review and technical support to customers and the sales team.
After receiving his BS degree in biological sciences, Dr. Srivastava attended the School of Veterinary Medicine at GB Pant University of Agriculture and Technology in India before pursuing a master’s degree in Pharmacology. He continued his education, earning a Ph.D. in Neuropharmacology from All India Institute of Medical Sciences in New Delhi. He obtained his post-doctoral fellowship and advanced training in neuropharmacology at University of Utah, USA and certification in clinical research from National Institute of Health, USA.